Issue: February 2019
February 07, 2019
1 min read
Save

ASCERTAIN

Issue: February 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Comparison of uninterrupted rivaroxaban (Xarelto, Janssen/Bayer) and warfarin in patients with nonvalvular AF who are undergoing radiofrequency cardiac ablation.